The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
New Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Aiming to Rein in Runaway Wound-Healing Responses
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) is a devastating disease, with a median survival as short as 3 years from the time of diagnosis and no pharmacological therapies yet approved by the U.S. Food and Drug Administration. To address the great unmet need for effective IPF therapy, a number of new drugs have recently been, or are now being, evaluated in clinical trials. The rationales for most of these therapeutic candidates are based on the current paradigm of IPF pathogenesis, in which recurrent injury to the alveolar epithelium is believed to drive aberrant wound healing responses, resulting in fibrosis rather than repair. Here we discuss drugs in recently completed or currently ongoing phase II and III IPF clinical trials in the context of their putative mechanisms of action and the aberrant repair processes they are believed to target: innate immune activation and polarization, fibroblast accumulation and myofibroblast differentiation, or extracellular matrix deposition and stiffening. Placed in this context, the positive results of recently completed trials of pirfenidone and nintedanib, and results that will come from ongoing trials of other agents, should provide valuable insights into the still-enigmatic pathogenesis of this disease, in addition to providing benefits to patients with IPF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269 · cited 1×
“macrophage phenotype(s) present in the lung (41, 42).”
BackgroundEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 3×
“inflammatory cells, new blood vessels, and fibroblasts migrate (28).”
BackgroundInfluentialA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 2×
“IL-13, the predominant profibrotic cytokine of Th2-type immunity (45), is one of the drivers of profibrotic alternative M2a-like macrophage activation.”
BackgroundReactive oxygen species, cellular redox systems, and apoptosis
Circu, M. L., & Aw, T. Y. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.12.022 · Cited by 3,340
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357
Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix
Wipff, P.-J., Rifkin, D. B., Meister, J.-J., & Hinz, B. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704042 · Cited by 1,346
Molecular mechanisms of N-acetylcysteine actions
Zafarullah, M., Li, W. Q., Sylvester, J., & Ahmad, M. (2003) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s000180300001 · Cited by 1,343
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 1×
“injury (120, 121), and/or (2) cyclic hypoxiareoxygenation during OSA leading to increased oxidative stress (121).”
BackgroundBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964
Adult-onset pulmonary fibrosis caused by mutations in telomerase
Tsakiri, K. D., Cronkhite, J. T., Kuan, P. J., Xing, C., Raghu, G., Weissler, J. C., Rosenblatt, R. L., Shay, J. W., & Garcia, C. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701009104 · Cited by 894
Perspective Article: Tissue repair, contraction, and the myofibroblast
Desmoulière, A., Chaponnier, C., & Gabbiani, G. (2005) · Wound Repair and Regeneration · doi:10.1111/j.1067-1927.2005.130102.x · Cited by 892
Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury
Hecker, L., Vittal, R., Jones, T., Jagirdar, R., Luckhardt, T. R., Horowitz, J. C., Pennathur, S., Martinez, F. J., & Thannickal, V. J. (2009) · Nature Medicine · doi:10.1038/nm.2005 · Cited by 852
Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
Self-citationBUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718
Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance
Hecker, L., Logsdon, N. J., Kurundkar, D., Kurundkar, A., Bernard, K., Hock, T., Meldrum, E., Sanders, Y. Y., & Thannickal, V. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008182 · Cited by 686
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652
A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002110 · Cited by 634
Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis
Georges, P. C., Hui, J.-J., Gombos, Z., McCormick, M. E., Wang, A. Y., Uemura, M., Mick, R., Janmey, P. A., Furth, E. E., & Wells, R. G. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00032.2007 · Cited by 577
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
Raghu, G., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Nathan, S. D., Wells, A. U., Collard, H. R., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00003 · Cited by 553
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction
Huang, X., Yang, N., Fiore, V. F., Barker, T. H., Sun, Y., Morris, S. W., Ding, Q., Thannickal, V. J., & Zhou, Y. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0050oc · Cited by 530
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-732oc · Cited by 500
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Noth, I., Anstrom, K. J., Calvert, S. B., de Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., & Olman, M. A. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0314oc · Cited by 463
Antifibrotic activities of pirfenidone in animal models
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454 · cited 1×
“It has pleiotropic antifibrotic, antiinflammatory, and antioxidant effects in animal and cell-based models (70, 71), but”
BackgroundPartial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-805oc · Cited by 420
Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370
A key role for nox4 in epithelial cell death during development of lung fibrosis
Carnesecchi, S., Deffert, C., Donati, Y., Basset, O., Hinz, B., Preynat-Seauve, O., Guichard, C., Arbiser, J. L., Banfi, B., Pache, J.-C., et al. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3829 · Cited by 290
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Raghu, G., Million-Rousseau, R., Morganti, A., Perchenet, L., Behr, J., & the MUSIC Study Group (2013) · European Respiratory Journal · doi:10.1183/09031936.00104612 · Cited by 277
Puthawala, K., Hadjiangelis, N., Jacoby, S. C., Bayongan, E., Zhao, Z., Yang, Z., Devitt, M. L., Horan, G. S., Weinreb, P. H., Lukashev, M. E., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-806oc · Cited by 272
Cited by
TGF-β1 Signaling and Tissue Fibrosis
Kim, K. K., Sheppard, D., & Chapman, H. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022293 · Cited by 800
“These studies highlight some additional sites of potential therapeutic intervention downstream from TGF-b1 activation that are studied in clinical and preclinical trials (Ahluwalia et al. 2014; Blackwell et al. 2014).”
BackgroundTsukui, T., Sun, K.-H., Wetter, J. B., Wilson-Kanamori, J. R., Hazelwood, L. A., Henderson, N. C., Adams, T. S., Schupp, J. C., Poli, S. D., Rosas, I. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15647-5 · Cited by 765
Extracellular matrix as a driver of progressive fibrosis
Herrera, J., Henke, C. A., & Bitterman, P. B. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93557 · Cited by 615
Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions
Della Latta, V., Cecchettini, A., Del Ry, S., & Morales, M. A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.012 · Cited by 514
Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis
Tashiro, J., Rubio, G. A., Limper, A. H., Williams, K., Elliot, S. J., Ninou, I., Aidinis, V., Tzouvelekis, A., & Glassberg, M. K. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00118 · Cited by 314
Metadata
- Authors
- Ahluwalia, N., Shea, B. S., & Tager, A. M.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-10-15
- Volume
- 190
- Issue
- 8
- Pages
- 867-878
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2045730105
- Cited by
- 235
- References
- 37
- FWCI
- 20.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.